Drug intelligence / Profile preview

RY108

Development stage: Preclinical
Lead developer: Reyon Pharmaceutical
Modality: Small Molecules

Overview

RY108 (also known as iN-EYD) is a preclinical-stage small molecule antifungal agent being developed by Reyon Pharmaceutical (이연제약). The drug is characterized as having a novel mechanism of action, distinct from existing antifungal classes, and was acquired through a technology transfer of patented intellectual property. It is currently undergoing preclinical evaluation for the treatment of various fungal infections. Specific details regarding its biological target and precise mechanism of action have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on RY108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RY108.

Explore the full profile